Dataset Information

CD8⁺ T cells contribute to survival in patients with COVID-19 and hematologic cancer.

ABSTRACT: Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 patients with cancer who were hospitalized for COVID-19, patients with hematologic cancer had higher mortality relative to patients with solid cancer. In two additional cohorts, flow cytometric and serologic analyses demonstrated that patients with solid cancer and patients without cancer had a similar immune phenotype during acute COVID-19, whereas patients with hematologic cancer had impairment of B cells and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibody responses. Despite the impaired humoral immunity and high mortality in patients with hematologic cancer who also have COVID-19, those with a greater number of CD8 T cells had improved survival, including those treated with anti-CD20 therapy. Furthermore, 77% of patients with hematologic cancer had detectable SARS-CoV-2-specific T cell responses. Thus, CD8 T cells might influence recovery from COVID-19 when humoral immunity is deficient. These observations suggest that CD8 T cell responses to vaccination might provide protection in patients with hematologic cancer even in the setting of limited humoral responses.

SUBMITTER: Bange EM

PROVIDER: S-EPMC8291091 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

CD8<sup>+</sup> T cells contribute to survival in patients with COVID-19 and hematologic cancer.

Bange Erin M EM Han Nicholas A NA Wileyto Paul P Kim Justin Y JY Gouma Sigrid S Robinson James J Greenplate Allison R AR Hwee Madeline A MA Porterfield Florence F Owoyemi Olutosin O Naik Karan K Zheng Cathy C Galantino Michael M Weisman Ariel R AR Ittner Caroline A G CAG Kugler Emily M EM Baxter Amy E AE Oniyide Olutwatosin O Agyekum Roseline S RS Dunn Thomas G TG Jones Tiffanie K TK Giannini Heather M HM Weirick Madison E ME McAllister Christopher M CM Babady N Esther NE Kumar Anita A Widman Adam J AJ DeWolf Susan S Boutemine Sawsan R SR Roberts Charlotte C Budzik Krista R KR Tollett Susan S Wright Carla C Perloff Tara T Sun Lova L Mathew Divij D Giles Josephine R JR Oldridge Derek A DA Wu Jennifer E JE Alanio Cécile C Adamski Sharon S Garfall Alfred L AL Vella Laura A LA Kerr Samuel J SJ Cohen Justine V JV Oyer Randall A RA Massa Ryan R Maillard Ivan P IP Maxwell Kara N KN Reilly John P JP Maslak Peter G PG Vonderheide Robert H RH Wolchok Jedd D JD Hensley Scott E SE Wherry E John EJ Meyer Nuala J NJ DeMichele Angela M AM Vardhana Santosha A SA Mamtani Ronac R Huang Alexander C AC

Nature medicine 20210520 7

Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 patients with cancer who were hospitalized for COVID-19, patients with hematologic cancer had higher mortality relative to patients with solid cancer. In two additional cohorts, flow cytometric and serologic analyses demonstrated that patients with solid cancer and patients without cancer had a similar immune phenotype duri ...[more]

PMID: 34017137

Similar Datasets

Project description:Cancer patients have increased morbidity and mortality from Coronavirus Disease 2019 (COVID-19), but the underlying immune mechanisms are unknown. In a cohort of 100 cancer patients hospitalized for COVID-19 at the University of Pennsylvania Health System, we found that patients with hematologic cancers had a significantly higher mortality relative to patients with solid cancers after accounting for confounders including ECOG performance status and active cancer status. We performed flow cytometric and serologic analyses of 106 cancer patients and 113 non-cancer controls from two additional cohorts at Penn and Memorial Sloan Kettering Cancer Center. Patients with solid cancers exhibited an immune phenotype similar to non-cancer patients during acute COVID-19 whereas patients with hematologic cancers had significant impairment of B cells and SARS-CoV-2-specific antibody responses. High dimensional analysis of flow cytometric data revealed 5 distinct immune phenotypes. An immune phenotype characterized by CD8 T cell depletion was associated with a high viral load and the highest mortality of 71%, among all cancer patients. In contrast, despite impaired B cell responses, patients with hematologic cancers and preserved CD8 T cells had a lower viral load and mortality. These data highlight the importance of CD8 T cells in acute COVID-19, particularly in the setting of impaired humoral immunity. Further, depletion of B cells with anti-CD20 therapy resulted in almost complete abrogation of SARS-CoV-2-specific IgG and IgM antibodies, but was not associated with increased mortality compared to other hematologic cancers, when adequate CD8 T cells were present. Finally, higher CD8 T cell counts were associated with improved overall survival in patients with hematologic cancers. Thus, CD8 T cells likely compensate for deficient humoral immunity and influence clinical recovery of COVID-19. These observations have important implications for cancer and COVID-19-directed treatments, immunosuppressive therapies, and for understanding the role of B and T cells in acute COVID-19.

Dataset Information

CD8⁺ T cells contribute to survival in patients with COVID-19 and hematologic cancer.

Publications

CD8<sup>+</sup> T cells contribute to survival in patients with COVID-19 and hematologic cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer.

Publications

CD8<sup>+</sup> T cells contribute to survival in patients with COVID-19 and hematologic cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

CD8⁺ T cells contribute to survival in patients with COVID-19 and hematologic cancer.